New vaccine combo aims to train immune system against Hard-to-Treat cancers
NCT ID NCT04117087
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a vaccine that targets mutated KRAS proteins, combined with two immunotherapy drugs (nivolumab and ipilimumab), in 27 patients with pancreatic or colorectal cancer that has been surgically removed. The goal is to see if the vaccine can safely boost the immune system's ability to recognize and fight cancer cells carrying KRAS mutations, which are common in these cancers. Researchers are primarily looking at side effects and immune response, not yet whether the treatment extends survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KRAS peptide vaccine (with Poly-ICLC adjuvant) plus nivolumab and ipilimumab
What this could lead to
If successful, this combination could help the immune system recognize and attack cancer cells with KRAS mutations, potentially delaying or preventing recurrence in pancreatic and colorectal cancers.
What could go wrong
This is a very early phase 1 trial with only 27 participants, so safety and immune response are the main focus—not yet proof of effectiveness. There is also a risk of serious side effects from the immunotherapy drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States